Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-11
2007-12-11
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S280000
Reexamination Certificate
active
10839323
ABSTRACT:
This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I wherein X1is (CH2)nor CO, n is 0 to 2 and R1, R2, R3and R4are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents
REFERENCES:
patent: WO98/01428 (1998-01-01), None
patent: WO98/33798 (1998-08-01), None
patent: WO 01/55148 (2001-08-01), None
patent: WO 02/059083 (2002-08-01), None
patent: WO 02/088095 (2002-11-01), None
patent: WO 02/100863 (2002-12-01), None
Lanier, M. et al., “Small Molecule Corticotropin-Releasing Factor Antagonists,”Expert. Opin. Ther. Patents2002, 12 (11): 1619-1630.
Owens, M.J., et al., “Corticotropin-Releasing Factor Antagonists,”CNS DrugsAug. 1999 12(2): 85-92.
O'Yang Counde
Schoenfeld Ryan Craig
Buckwalter Brian L.
Roche Palo Alto LLC
LandOfFree
Heterocyclic derivatives as CRF antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic derivatives as CRF antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic derivatives as CRF antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3877476